Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ocata Therapeutics's Days Inventory for the
three
months ended in Sep. 2015 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocata Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2015 was 0.00.
Ocata Therapeutics Inventory Turnover Historical Data
The historical data trend for Ocata Therapeutics's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ocata Therapeutics's Days Inventory for the
three
months ended in Sep. 2015 is calculated as:
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocata Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Ocata Therapeutics Inventory Turnover Related Terms
Thank you for viewing the detailed overview of Ocata Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocata Therapeutics (Ocata Therapeutics) Business Description
Ocata Therapeutics Inc was incorporated in Nevada under the name Two Moon Kachinas Corp. on May 18, 2000. The Company is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. It also has a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. It has developed a human photoreceptor progenitor cell. In the U.S., one of the Company's ongoing clinical trials is a Phase 1/2 study for treating dry AMD patients by injection of RPE cells made in culture from an hESC line. It is also conducting Phase 1/2 studies in both the U.S. and the U.K. for the treatment of SMD patients using the RPE cell injections. The Company is conducting three trials in cooperation with retinal surgeons at the top eye hospitals in the U.S. and the U.K. including: Jules Stein Eye Institute (UCLA), Wills Eye Institute, Bascom Palmer Eye Institute (University of Miami) and Massachusetts Eye and Ear Infirmary. As of March 27, 2014, the Company had 46 issued patents and 178 pending patent applications filed, a substantial portion of which pertain to its active product development programs. The Company competes with Pfizer, Regenerative Patch Technologies and the Riken Center for Developmental Biology (Japan), among others. The Company's research and development activities are subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCAT has been successfully added to your 